Olutasidenib Combination Therapy
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 45 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- Rigel Pharmaceuticals
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2035
- NCT Identifier
- NCT06597734
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.